A Case of Typhlitis Developed after Chemotherapy with Irinotecan and Cisplatin in a Patient with Small Cell Lung Carcinoma.
10.4046/trd.2012.73.5.288
- Author:
Eun Hye JI
1
;
Young Min KIM
;
Soo Jeong KIM
;
Soo Jeong YEOM
;
Sung Eun HA
;
Hyeon Hui KANG
;
Ji Young KANG
;
Sang Haak LEE
;
Hwa Sik MOON
Author Information
1. Department of Internal Medicine, The Catholic University of Korea College of Medicine, Seoul, Korea. mdlee@catholic.ac.kr
- Publication Type:Case Report
- Keywords:
Typhlitis;
Irinotecan;
Small Cell Lung Carcinoma
- MeSH:
Camptothecin;
Cisplatin;
Colitis;
Colonic Neoplasms;
DNA;
DNA Topoisomerases, Type I;
Hematologic Neoplasms;
Humans;
Leukemia;
Lymphoma;
Peritonitis;
Sepsis;
Small Cell Lung Carcinoma;
Typhlitis
- From:Tuberculosis and Respiratory Diseases
2012;73(5):288-291
- CountryRepublic of Korea
- Language:English
-
Abstract:
Typhlitis is a necrotizing colitis that usually occurs in neutropenic patients and develops most often in patients with hematologic malignancies such as leukemia and lymphoma. Typhlitis may proceed to bowel perforation, peritonitis and sepsis, which requires immediate treatment. Irinotecan is a semisynthetic analogue of the natural alkaloid camptothecin which prevents DNA from unwinding by inhibition of topoisomerase I. It is mainly used in colon cancer and small cell lung carcinoma (SCLC), of which the most common adverse effects are gastrointestinal toxicities. To the best of our knowledge, no case of typhlitis after chemotherapy with a standard dose of irinotecan in a solid tumor has been reported in the literature. We, herein, report the first case of typhlitis developed after chemotherapy combining irinotecan and cisplatin in a patient with SCLC.
